期刊
CANCERS
卷 11, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/cancers11010105
关键词
pan-HER inhibitor; triple-negative breast cancer
类别
资金
- Yang-Ming Branch of Taipei City Hospital [10601-62-020, 10701-62-030]
- Yen Tjing Ling Medical Foundation [CI-107-10]
- Ministry of Science and Technology, Taiwan [MOST 104-2628-B-075-001-MY3, 105-2314-B-075-044-MY3]
- Taipei Veterans General Hospital [V106C-101, V107C-025, V107C-016, V106D27-002-MY2-2]
- TVGH-NTUH Joint Research Program from Taipei Veterans General Hospital [VN106-07]
- Ministry of Health and Welfare, Executive Yuan, Taiwan [MOHW107-TDU-B-212-112015]
- National Taiwan-University Hospital
Triple-negative breast cancer (TNBC) is a complex disease associated with the aggressive phenotype and poor prognosis. TNBC harbors heterogeneous molecular subtypes with no approved specific targeted therapy. It has been reported that HER receptors are overexpressed in breast cancer including TNBC. In this study, we evaluated the efficacy of varlitinib, a reversible small molecule pan-HER inhibitor in TNBC. Our results showed that varlitinib reduced cell viability and induced cell apoptosis in most TNBC cell lines but not in MDA-MB-231 cells. MEK and ERK inhibition overcame resistance to varlitinib in MDA-MB-231 cells. Varlitinib inhibited HER signaling which led to inhibition of migration, invasion and mammosphere formation of TNBC cells as well as significant suppression of tumor growth of MDA-MB-468 xenograft mouse model. In summary, these results suggest that HER signaling plays an important role in TNBC progression and that pan-HER inhibition is potentially an effective treatment for TNBC patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据